Fatty liver associated with metabolic dysfunction is common, affects a quarter of the
population, and has no approved drug therapy. Although pharmacotherapies are in …

Hepatocellular carcinoma (HCC) is a leading lethal malignancy worldwide. However, the
molecular mechanisms underlying liver carcinogenesis remain poorly understood. Over the …

Genome-wide association studies (GWAS) have now correlated hundreds of genetic
variants with complex genetic diseases and drug efficacy. Functional characterization of …

Simple Summary Hepatocellular carcinoma (HCC) is an aggressive human cancer and is
caused as consequences of chronic liver diseases. Although HCC is more common in …

Non-alcoholic fatty liver disease (NAFLD) is a multifaceted metabolic disorder, whose
spectrum covers clinical, histological and pathophysiological developments ranging from …

Nonalcoholic fatty liver disease (NAFLD) is characterised by hepatic steatosis, inflammation,
and insulin resistance. The role of long noncoding RNA (lncRNA)-regulated pyroptosis in …

Long non-coding RNAs (lncRNAs) show great potential as therapeutic targets in many
diseases including hepatocellular carcinoma (HCC). Here, we aimed to investigate the …

Long noncoding RNAs (lncRNAs) are implicated as novel drivers in hepatocellular
carcinoma (HCC), but the underlying mechanisms of this relationship with …

Despite decades of research, effective therapies for metabolic (dysfunction)-associated fatty
liver disease (MAFLD) are lacking. An increasing body of evidence suggests that epigenetic …

Non-alcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic
liver disease worldwide. Early identification and prompt treatment are critical to optimize …